IKCSNA26 Abstract Titles

Full abstracts will be available to conference registrants on November 14, 2026, and to the public on November 19, 2026.

IKCSNA26 – Dallas, Texas
Artificial Intelligence, Digital Health & Computational Oncology
A1: A Highly Sensitive Blood-Based Transcriptomic Platform for Detecting Early-Stage Renal Cell Carcinoma Erdal Toprak, University of Texas Southwestern Medical Center
A2: Single cell trajectory mapping identifies divergent mesenchymal and antigen-presenting tumor cell states in sarcomatoid renal cell carcinoma Gabriel Alencar, University of Virginia, Charlottesville, Virginia/USA
A3: A dual-axis transcriptomic model of clear cell renal cell carcinoma evolution linking driver mutations and the tumor microenvironment to prognosis and treatment benefit Roy Elias, Johns Hopkins School of Medicine
A4: Digital twins as ethical enablers of next-generation ccRCC bone metastasis research Eleonora Dondossola, UT MD Anderson, Houston, TX, USA
Basic Science/Tumor Biology/Microenvironment
B1: Spatial Xenium Profiling of ccRCC and Sarcomatoid RCC Regions Reveals Distinct Immune, Stromal, and Matrix-Remodeling Programs Chen Yao, UT Southwestern Medical Center
B2: Sleeping Beauty transposon screens to identify mechanisms of resistance to HIF-2α antagonists in ccRCC Eliot Zhu, UT Southwestern Medical Center
B3: Modulating EGFR signaling pathways by glycosylation for cancer treatment Hongyi Liu, Johns Hopkins University
B4: BAP1/PBRM1 Double-Mutant ccRCC Shows Increased DNA Damage Repair Dysregulation Jun Yang, The University of Texas Southwestern Medical Center
B5: Genome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer Jun Fang, University of texas southwestern midcal center
B6: Direct in vivo activation of tumor-infiltrating lymphocytes by a multivalent nanoengager drives systemic antitumor immunity Man Wang, The University of Texas Southwestern Medical Center, Dallas, Texas, US
B7: Exploiting Nucleolar Hypertrophy to Target Kidney Cancer Maralice Conacci Sorrell, University of Texas Southwestern Medical Center
B8: Discovery and Development of Targeted Therapeutics in Metastatic Chromophobe Renal Cell Carcinoma Eleanor Irion, McGovern Medical School , Houston, TX
B9: PTGES promotes acquired resistance to HIF-2α inhibition in clear cell renal cell carcinoma Qing Zhang, University of Texas Southwestern
B10: From microRNA Loss to Disrupted Nephrogenesis: Uncovering the Crucial Role of DROSHA in Kidney Development Prerna Kulshrestha, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA
B11: An Innovative Approach to Developing Syngeneic Kidney Cancer Models Harboring VHL Loss and MYC Activation Ramesh Butti, Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
B12: A Single Chromosome 3p Break Initiates Clear Cell Renal Cell Carcinoma Evolution Rashmi Dahiya, Children Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas, United States
B13: Characterizing the Metabolic Consequences of VHL Missense Mutations in Clear Cell Renal Cell Carcinoma Siyu Yin, UTSouthwestern Medical Center, Dallas, TX, USA
B14: Functional interrogation of tumor-gained enhancers reveals a PLXNA1 dependency that sustains AXL signaling in clear-cell renal cell carcinoma Tao Wang, Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA
B15: Oxygen-Aware Patient-Derived Tumor Fragments as a Functional Platform to Study RCC Immunotherapy Response Tao Yue, University of Texas Southwestern Medical Center at Dallas
B16: TAZ and SRF Cooperate to Promote Immune Escape in Sarcomatoid Renal Cell Carcinoma Thomas Carroll, UT Southwestern Med Ctr Dallas, TX USA

B17: Tumor Microenvironment Modulation by Cyclopamine Tartrate Enhances Immunotherapy Response in Renal Cell Carcinoma
Tianyuan Wang, UT Southwestern Medical Center, Dallas, TX

B18: Partial ATG7 Loss Shapes Autophagy and Tumor Phenotype in Translocation Renal Cell Carcinoma
Tolulope Ayo, Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.

B19: Hijacking VHL-HIF signaling to prime kidney cancer cells for death
Weibo Luo, UT Southwestern Medical Center, Dallas, TX, USA

B20: Alkylating agents sensitize SLFN11-high ccRCC to PARP inhibitorsPARP inhibitors have demonstrated notable clinical benefit, but their effectiveness is currently restricted to patients with BRCA1/2 mutations. How to enhance sensitivity of BRCA1/2-wildtype
Yingfei Wang, UT Southwestern Mecial Center, Dallas, TX

Disparities in Cancer, Care, and Access

C1: Social Vulnerability in Metastatic Renal Cell Carcinoma
Jillian Thompson, Emory University School of Medicine, Atlanta, GA, United States of America

C2: Stage IV Kidney Cancer Non-Treatment Rates and First-Line Treatment Patterns from the National Cancer Database
Panayiotis Kontoyiannis MD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX

Treatment Toxicities and Symptom Management

D1: Durable Disease Control with Markedly Reduced-Dose Belzutifan in Advanced Clear-Cell Renal Cell Carcinoma
Panayiotis Kontoyiannis MD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX

D2: Intraperitoneal Alteplase for Refractory Loculated Malignant Ascites in Advanced Renal Cell Carcinoma
Panayiotis Kontoyiannis MD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX

Patient-reported Outcomes

E1: Navigating Uncertainty: Shared Decision-Making, Patient Priorities, and Decisional Regret in Adjuvant Renal Cell Carcinoma
Dena Battle, KCCure

Post-treatment Surveillance

F1: Late, Imaging-Occult Gastrointestinal Metastases from Renal Cell Carcinoma
Sravya Gundapaneni, University of Maryland Capital Region Medical Center

F2: Ultrasensitive ctDNA Kinetics and Association with Survival in Oligoprogressive Renal Cell Carcinoma Patients Treated with Metastasis Directed Therapy
Zakaria El Kouzi, University of Texas MD Anderson Houston, Texas

Prevention and Screening

G1: Body weight history during the adult lifespan and survival in renal cell carcinoma patients
Kellen T. Higgins, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Quality of Care and Quality Improvement

H1: Subcutaneous versus Intravenous Immune Checkpoint Inhibitors, Treatment Burden, and Care Delivery for Patients with Renal Cell Carcinoma
Sahil Doshi, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Real-World Evidence

I1: A RISK-ADAPTED FRAMEWORK FOR ADJUVANT PEMBROLIZUMAB PLUS BELZUTIFAN IN RESECTED CLEAR CELL RENAL CELL CARCINOMA
Arighno Das, University of Texas MD Anderson Cancer Center

I2: Clinical Characteristics and Systemic Therapy in Birt-Hogg-Dubé Patients with Renal Tumors
Ava Jahn, Memorial Sloan Kettering Cancer Center, New York, New York

I3: Short-Term Healthcare Utilization Following Percutaneous Thermal Ablation Versus Partial and Radical Nephrectomy for Kidney Cancer: A Real-World Medicare Analysis
Alysha M. McGovern, MBA, Boston Scientific, Marlborough, MA, USA

I4: Clinical Outcomes of Extended-Interval Pembrolizumab Dosing in Metastatic Renal Cell Carcinoma: A Real-World Analysis from the Canadian Kidney Cancer Information System (CKCis)
Ja Yoon Heo, Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

I5: Real-world effectiveness and tolerability of first-line cabozantinib + nivolumab (CaboNivo) in patients with bone metastases (BM): CaboCombo post-hoc analysis
Philippe Barthélémy, Medical Oncology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

I6: Real world evidence of belzutifan use in patients with Von Hippel-Lindau (VHL) disease
Rimas Lukas, Northwestern University, Department of Neurology, Chicago, IL, USA

I7: Patient Characteristics and Survival Outcomes of Early-Stage Relapsed, Metastatic Renal Cell Carcinoma
Virginia Olivier, Indiana University School of Medicine, Indianapolis, IN, USA

Surgery & Localized Interventions

J1: Clinical Features, Genomic Alterations, and Outcomes of Patients Undergoing Cytoreductive Nephrectomy for Renal Cell Carcinoma
Virginia Olivier, Indiana University School of Medicine, Indianapolis, IN

J2: Criteria Provide Less Prognostic Discrimination Than Multilevel Risk Models After Nephrectomy for Renal Cell Carcinoma
Michael Staehler, Ludwig-Maximilians University of Munich, Munich, Germany

Survivorship

K1: Outcomes of Involuntary Active Surveillance for Small Renal Masses
Michael Staehler, Ludwig-Maximilians University Munich, Munich, Germany

Therapeutics

L1: Darlifarnib+cabozantinib in renal cell carcinoma (RCC): Updated FIT-001 Ph1a results
Adam E. Singer, Division of Hematology-Oncology, University of California Los Angeles Medical Center, Los Angeles, CA, USA

L2: Efficacy and safety of cabozantinib plus nivolumab (C+N) versus sunitinib (SUN) by baseline liver metastasis status in patients with advanced renal cell carcinoma (aRCC)
Amishi Y. Shah, MD Anderson Cancer Center, Houston, TX, USA

L3: XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC): Interim Phase 1 results
Benjamin Garmezy, Sarah Cannon Research Institute, Nashville, TN, USA

L4: Characterization and Clinical Development of PF-08634404, a Tetravalent PD-1/VEGF Bispecific Antibody, in Locally Advanced or Metastatic Renal Cell Carcinoma (la/mRCC)
Brian Rini, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

L6: Belzutifan plus zanzalintinib versus belzutifan for advanced renal cell carcinoma (RCC) during or after anti–PD-(L)1 and VEGF-TKI therapy: Phase 3 LITESPARK-034 study
Laurence Albiges, Gustave Roussy, Université Paris-Saclay, Villejuif, France

L7: Modulation of the Bone Immune Microenvironment by Cabozantinib plus Nivolumab in Bone-Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Matthew T Campbell, University of Texas MD Anderson Cancer Center, Houston, TX, USA

L8: Oncorella-1: a Phase I/II study of orellanine in patients with metastatic clear-cell or papillary renal cell carcinoma and ESKD requiring hemodialysis
Nataliya Mar, University of California, Irvine, CA, USA

L9: The First Sequential Multiple Assignment Randomized Trial (SMART) in Metastatic Renal Cell Carcinoma: Response Rate Did Not Identify the Optimal Survival Strategy
Pavlos Msaouel, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

L10: Updated analysis of cabozantinib plus nivolumab (C+N) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) by baseline bone metastasis status
Andrea B. Apolo, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

L11: EXPLORE-RCC: A Phase II Trial of Neoadjuvant Zanzalintinib Plus Nivolumab in Locally Advanced and/or Surgically Challenging Clear Cell Renal Cell Carcinoma
Qian Qin, University of Texas Southwestern, Dallas, TX

L12: Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC)
Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY

L13: Phase 3 study to assess the safety and efficacy of 177Lu-girentuximab in advanced, relapsed or recurrent ccRCC (LUTEON)
Sumanta Pal, City of Hope Comprehesive Cancer Center, Duarte, CA USA

L14: Phase 1b Dose Escalation of a Multicenter, Open-Label Trial of Tivozanib Plus HC-5404 in Patients With Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Thomas E. Hutson, Texas Oncology, Abilene, TX, USA

Treatment Toxicities and Symptom Management

M1: Immune-related toxicities of first-line ipilimumab/nivolumab in older versus younger patients with metastatic clear cell renal cell carcinoma: An expanded multi-institutional analysis
Antonio Ocejo, Memorial Sloan Kettering Cancer Center, New York, NY, US

M2: Pembrolizumab-Induced Vogt-Koyanagi-Harada-Like Disease in a Patient with Metastatic Renal Cell Carcinoma
Hadi Mansour, Henry Ford Hospital, Detroit, MI, USA

Translational Research

N1: Chromatin-Enabled HIF-2α Regulation of PTHrP Is a Therapeutically Actionable Driver of Paraneoplastic Hypercalcemia in Clear Cell Renal Cell Carcinoma
Arijit Mal, Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA

N2: Diet and the gut microbiome among patients receiving cabozantinib-based regimens for advanced renal cell carcinoma: a prospective, multicenter, observational cohort study
Brendan Guercio, Wilmot Cancer Institute, University of Rochester, Rochester, NY

N3: Utilizing circulating tumor cells (CTCs) and cytokines to predict immunotherapy treatment response in patients with renal cell carcinoma (RCC)
Caroline Greenstone, Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

N4: SPATIAL AND MOLECULAR LANDSCAPE IN CLEAR CELL RENAL CELL CARCINOMA BONE METASTATIC PATIENTS
Eleonora Dondossola, UT MD Anderson, Houston, TX, USA

N5: The DNA Damage Immune Response Signature Associates with Benefit from Atezolizumab Plus Bevacizumab in RCC
Kaela Makins, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

N6: Mechanistic investigation of paraneoplastic anemia in renal cell carcinoma through integrated clinical and preclinical models
Muhammad Nazmul Hasan, University of Texas Southwestern Medical Center, Kidney Cancer Program, Dallas, Texas, USA

N7: Development and Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma with Spontaneous Venous Tumor Thrombus.
Adriano de Oliveira Bezerra, A.C.Camargo Cancer Center, Sao Paulo/Brazil; National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation São Paulo/Brazil

N8: Cluster of Differentiation 70 (CD70) Expression Predicts Benefit from Adjuvant Checkpoint Inhibition in Renal Cell Carcinoma
Vitor Abreu de Góes, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA

N9: Rewiring Nitrogen Metabolism to Sustain Pyrimidine Biosynthesis in Human clear ccell RCC
Lin Lin, UT Southwestern Medical center, Dallas, Tx

Tumor Biomarkers and Pathology

O1: Utility of Circulating Tumor DNA in Patients with Renal Cell Carcinoma at High Clinical Risk of Recurrence After Resection
Lin Lin, UT Southwestern Medical Center

O2: FASN expression is associated with tyrosine kinase inhibitor resistance in advanced renal cell carcinoma
Jonah Butler, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

O3: Ribosomal Proteins and Wilms Tumorigenesis
Hongbing Liu, Department of Pediatrics Tulane school of Medicine, New Orleans, Louisiana

O4: Clonal hematopoiesis, treatment associations, and germline TERT architecture in renal cell carcinoma (RCC)
Maxine Sun, Montreal Heart Institute, Montreal, Canada; Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Canada

O5: POSTOPERATIVE CTDNA ELEVATION REVEALS PERSISTENT SYSTEMIC DISEASE IN ADVANCED CLEAR CELL RENAL CELL CARCINOMA
Sephora Dafinescu, Wayne State University School of Medicine, Detroit, MI

O6: Proteome-Wide Profiling Reveals Remodeling of Humoral Immunity Following Immune Checkpoint Inhibition in Renal Cell Carcinoma
Tuoqi Wu, University of Texas Southwestern Medical Center, Dallas, TX, USA

O7: ctDNA DETECTION STRONGLY PREDICTS RADIOGRAPHIC RENAL CELL CARCINOMA RECURRENCE
Jason Scovell, Cleveland Clinic Foundation

Surgery & Localized Interventions

P1: Stereotactic body radiation therapy for renal cell carcinoma with inferior vena cava thrombus: an international multi-institutional cohort
Lin Lin, Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, US

P2: Multidisciplinary management of Renal Cell Carcinoma with Intravascular Recurrence
Davis Temple, Department of Urology, University of Virginia, Charlotteville, VA

P3: Intraoperative Sodium Acetate Infusion to Mitigate Acute Kidney Injury After Robotic Partial Nephrectomy: A Nomogram-Guided Risk-Stratified Analysis
Jeffrey Cadeddu, UT Southwestern Medical Center, Dallas, TX USA

P4: Clinical Predictors of Progression and Survival After Pre-Surgical Systemic Therapy and Nephrectomy for Renal Cell Carcinoma
Jesse Persily, UT Southwestern Medical Center, Dallas, Texas/USA

P5: CT-guided Cryoablation for Biopsy-proven T1a Renal Cell Carcinoma: Long-term Oncological Outcomes from the Prospective Multinational EuRECA Registry
Ole Graumann, Department of Radiology, Aarhus University Hospital, Denmark

Health Equity & Global Oncology

Q1: Diagnostic and surveillance imaging burden in patients undergoing evaluation for a renal mass: real-world analysis of US claims data
Pratik Kanabur, Virginia Commonwealth University

Imaging

R1: Exploiting the Krebs Defect: [18F]FDG PET/CT for Extent of Disease Evaluation in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Simone Krebs, The University of Texas MD Anderson Cancer Center, Houston, Texas